What the trial was testing
The 2IQP enrolled 319 patients with type 2 diabetes. The study was sponsored by Tandem Diabetes Care, Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
Blood sugar levels dropped 0.9 percentage points with automated delivery versus 0.3 points with standard insulin.
The New England journal of medicine · 2025 · NCT05785832
These findings — that blood sugar control improved nearly three times more than standard insulin — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 319 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 2 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This automated insulin delivery system is FDA-approved and available now for type 2 diabetes. If you're currently taking insulin and struggling to control your blood sugar, ask your doctor whether an automated insulin pump might work for you. These systems adjust your insulin automatically throughout the day.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 2 diabetes trials
A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes mellitus
Effect of Sleep Extension on Ceramides in People with Overweight and Obesity
The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).